Namilumab for Sarcoidosis
This trial is studying whether a combination of two drugs is better than either drug alone in treating patients with advanced melanoma.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2016 Phase 2 trial • 122 Patients • NCT02129777
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How extensive is the recruitment process for this medical experiment?
"Yes, according to clinicaltrials.gov the trial is currently engaging with potential participants. Initially posted on April 30th 2022 and recently updated on November 22nd 2022, this study seeks 100 individuals across 16 different sites."
Are there still opportunities for enrollment in this trial?
"The information on clinicaltrials.gov attests to the fact that the recruitment process for this medical study is ongoing; it was first introduced in April 2022 and recently refreshed at the end of November."
Has Namilumab received regulatory clearance from the FDA?
"Despite the lack of efficacy data, namilumab was given a safety score of 2 due to limited evidence pointing towards its safety."
How many sites have oversight of this trial?
"At present, this medical study is being conducted at 16 sites located in Pittsburgh, Charlottesville, Rochester and an array of other cities. Those looking to participate should pick a local site whenever possible so as to reduce travel related strain on themselves."